170 related articles for article (PubMed ID: 18342157)
1. [Observational survey on variations of prostate cancer incidence by stage in the Nord-Pas-de-Calais region between 1998 and 2004].
Flamand V; Zini L; Salleron J; Fantoni JC; Biserte J; Villers A
Prog Urol; 2008 Jan; 18(1):53-9. PubMed ID: 18342157
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
Adolfsson J; Garmo H; Varenhorst E; Ahlgren G; Ahlstrand C; Andrén O; Bill-Axelson A; Bratt O; Damber JE; Hellström K; Hellström M; Holmberg E; Holmberg L; Hugosson J; Johansson JE; Petterson B; Törnblom M; Widmark A; Stattin P
Scand J Urol Nephrol; 2007; 41(6):456-77. PubMed ID: 17934985
[TBL] [Abstract][Full Text] [Related]
3. Decline in the overall incidence of regional-distant prostate cancer in Olmsted County, MN, 1980-2000.
Mullan RJ; Jacobsen SJ; Bergstralh EJ; Slezak JM; Tindall DJ; Lieber MM; Roberts RO
BJU Int; 2005 May; 95(7):951-5. PubMed ID: 15839911
[TBL] [Abstract][Full Text] [Related]
4. The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK.
Mokete M; Shackley DC; Betts CD; O'Flynn KJ; Clarke NW
BJU Int; 2006 Feb; 97(2):266-9. PubMed ID: 16430626
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen as surrogate for characterizing prostate cancer subgroups.
Sandblom G; Holmberg L; Damber JE; Hugosson J; Johansson JE; Lundgren R; Mattsson E; Nilsson J; Varenhorst E
Scand J Urol Nephrol; 2002; 36(2):106-12. PubMed ID: 12028683
[TBL] [Abstract][Full Text] [Related]
6. The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival.
Varenhorst E; Garmo H; Holmberg L; Adolfsson J; Damber JE; Hellström M; Hugosson J; Lundgren R; Stattin P; Törnblom M; Johansson JE
Scand J Urol Nephrol; 2005; 39(2):117-23. PubMed ID: 16019764
[TBL] [Abstract][Full Text] [Related]
7. [Epidemiology of prostate cancer in the Limousin area].
Druet-Cabanac M; Colombeau P; Preux PM; Paulhac P; Vergnenegre A; Dumas JP
Prog Urol; 2002 Apr; 12(2):226-31. PubMed ID: 12108336
[TBL] [Abstract][Full Text] [Related]
8. [Cancer of the prostate in France: results of the survey CCAFU-FRANCIM].
Soulié M; Villers A; Grosclaude P; Menegoz F; Schaffer P; Mace-Lesec'h J; Sauvage-Machelard M; Molinier L; Grand A
Prog Urol; 2001 Jun; 11(3):478-85. PubMed ID: 11512461
[TBL] [Abstract][Full Text] [Related]
9. A 6-year analysis of the clinicopathological profile of patients with prostate cancer at the University Hospital of the West Indies, Jamaica.
Coard KC; Skeete DH
BJU Int; 2009 Jun; 103(11):1482-6. PubMed ID: 19076136
[TBL] [Abstract][Full Text] [Related]
10. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
Roobol MJ; Grenabo A; Schröder FH; Hugosson J
J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
[TBL] [Abstract][Full Text] [Related]
11. [Epidemiological trends in prostate cancer over the last years].
Luján Galán M; Páez Borda A; Chiva Robles V; Santonja Garriga C; Romero Cajigal I; Berenguer Sánchez A
Arch Esp Urol; 2004 Oct; 57(8):817-25. PubMed ID: 15560270
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer after heart transplantation: unicenter case-control study.
Mohammadi S; Silvaggio G; Bonnet N; Berberian G; Dorent R; Bikter M; Pavie A; Gandjbakhch I
J Heart Lung Transplant; 2005 Aug; 24(8):995-7. PubMed ID: 16102432
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen kinetics in screen-detected prostate cancer in Japan.
Takechi H; Ito K; Yamamoto T; Miyakubo M; Ohi M; Suzuki K
Urology; 2008 Nov; 72(5):1111-5. PubMed ID: 18342926
[TBL] [Abstract][Full Text] [Related]
14. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.
Etzioni R; Gulati R; Falcon S; Penson DF
Med Decis Making; 2008; 28(3):323-31. PubMed ID: 18319508
[TBL] [Abstract][Full Text] [Related]
15. [Management of locally advanced prostatic adenocarcinoma in France. OCTAVE observational survey].
Villers A; Haffner J; Taibi A; Lucas C; Wibault P
Prog Urol; 2006 Jun; 16(3):316-9. PubMed ID: 16821343
[TBL] [Abstract][Full Text] [Related]
16. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality.
Zelefsky MJ; Shi W; Yamada Y; Kollmeier MA; Cox B; Park J; Seshan VE
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1350-6. PubMed ID: 19515504
[TBL] [Abstract][Full Text] [Related]
17. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
[TBL] [Abstract][Full Text] [Related]
18. Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era.
Tonita JM; Skarsgard D; Muhajarine N
Cancer Causes Control; 2009 Mar; 20(2):201-9. PubMed ID: 18825504
[TBL] [Abstract][Full Text] [Related]
19. Geographical variation in incidence of prostate cancer in Sweden.
Stattin P; Johansson R; Lodnert R; Andrén O; Bill-Axelsson A; Bratt O; Damber JE; Hellström M; Hugosson J; Lundgren R; Törnblom M; Varenhorst E; Johansson JE
Scand J Urol Nephrol; 2005; 39(5):372-9. PubMed ID: 16257838
[TBL] [Abstract][Full Text] [Related]
20. [Prostate cancer screening (II): is prostate cancer a public health problem? Update of incidence and mortality figures in France from 1982 to 1990].
Grosclaude P; Menegoz F; Schaffer P; Macé Lesec'h J; Arveux P; Le Mab G; Soulié M; Villers A
Prog Urol; 1997 Sep; 7(4):647-54. PubMed ID: 9410328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
